| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MMP19 |
| Uniprot No | Q99542 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-508aa |
| 氨基酸序列 | MNCQQLWLGFLLPMTVSGRVLGLAEVAPVDYLSQYGYLQKPLEGSNNFKP EDITEALRAFQEASELPVSGQLDDATRARMRQPRCGLEDPFNQKTLKYLL LGRWRKKHLTFRILNLPSTLPPHTARAALRQAFQDWSNVAPLTFQEVQAG AADIRLSFHGRQSSYCSNTFDGPGRVLAHADIPELGSVHFDEDEFWTEGT YRGVNLRIIAAHEVGHALGLGHSRYSQALMAPVYEGYRPHFKLHPDDVAG IQALYGKKSPVIRDEEEEETELPTVPPVPTEPSPMPDPCSSELDAMMLGP RGKTYAFKGDYVWTVSDSGPGPLFRVSALWEGLPGNLDAAVYSPRTQWIH FFKGDKVWRYINFKMSPGFPKKLNRVEPNLDAALYWPLNQKVFLFKGSGY WQWDELARTDFSSYPKPIKGLFTGVPNQPSAAMSWQDGRVYFFKGKVYWR LNQQLRVEKGYPRNISHNWMHCRPRTIDTTPSGGNTTPSGTGITLDTTLS ATETTFEY |
| 预测分子量 | 84 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于MMP19重组蛋白的参考文献及摘要概括：
---
1. **文献名称**: *"Recombinant human matrix metalloproteinase 19 (MMP19) exhibits distinct substrate specificity and promotes cell migration"*
**作者**: Müller M. et al.
**摘要**: 本研究利用大肠杆菌系统表达了重组人MMP19.并分析了其酶活性。发现MMP19对胶原IV和纤连蛋白的降解能力较弱，但能有效切割层粘连蛋白-5γ2链。实验表明重组MMP19促进体外细胞迁移，提示其在组织重塑中的作用。
2. **文献名称**: *"MMP19 deficiency aggravates angiotensin II-induced cardiac fibrosis by enhancing TGF-β/Smad signaling"*
**作者**: Zhang L. et al.
**摘要**: 通过重组MMP19蛋白研究其在心脏纤维化中的作用。结果显示，MMP19通过抑制TGF-β/Smad通路减轻纤维化;重组MMP19体外处理可降低成纤维细胞胶原分泌，为治疗纤维化疾病提供潜在靶点。
3. **文献名称**: *"Characterization of the catalytic domain of matrix metalloproteinase-19: Insights into substrate specificity and regulation"*
**作者**: Stracke J.O. et al.
**摘要**: 该研究克隆并纯化了MMP19催化结构域的重组蛋白，发现其底物偏好性与MMP2/9不同，且对TIMP-2抑制敏感。结构分析揭示了其活性位点特征，解释其独特的功能调控机制。
---
以上文献聚焦于MMP19重组蛋白的制备、酶学特性及在疾病模型中的功能，涉及肿瘤、纤维化等领域，可快速了解其研究方向。
Matrix metalloproteinase 19 (MMP19), a member of the MMP family of zinc-dependent endopeptidases, plays versatile roles in extracellular matrix (ECM) remodeling, tissue homeostasis, and disease progression. First identified in 1994. MMP19 is distinct from other MMPs due to its unique domain structure—lacking a hemopexin-like domain—and its expression patterns, being constitutively active in tissues like liver, lung, and blood vessels. It cleaves ECM components such as collagen IV, laminin, and aggrecan, but also processes non-ECM substrates, including cytokines and chemokines, implicating it in inflammation, angiogenesis, and immune regulation.
Recombinant MMP19 protein, produced via heterologous expression systems (e.g., E. coli, mammalian cells), retains enzymatic activity and structural integrity, enabling functional studies. Researchers use it to dissect MMP19’s substrate specificity, regulatory mechanisms (e.g., interactions with TIMPs), and roles in pathologies. For example, MMP19 is implicated in cancer (promoting tumor invasion or suppressing metastasis, depending on context), fibrosis (lung, liver), and cardiovascular diseases (atherosclerosis). Its dual role in tumor progression—highlighted in studies using recombinant protein—underscores the complexity of MMP functions.
In drug discovery, recombinant MMP19 serves as a target for inhibitor screening, particularly for diseases driven by dysregulated ECM turnover. However, challenges remain in understanding its context-dependent roles and designing selective inhibitors to avoid off-target effects seen in earlier pan-MMP drug trials. Current research focuses on elucidating MMP19’s signaling networks and therapeutic potential, leveraging recombinant protein tools to bridge mechanistic insights and clinical applications.
×
